报价延迟最少15分钟:2026/01/09 22:24 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.00/-3.57
|
|
企业价值
1.44B
|
| 资产负债 |
|
每股账面净值
2.42
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
43.27M
|
|
每股收益
0.51
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD. |
